Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ADCT-701 |
Synonyms | |
Therapy Description |
ADCT-701 is an antibody-drug conjugate (ADC) comprising an antibody targeting DLK-1 linked to the cytotoxic agent SG3199, which potentially decreases tumor growth (Cancer Res (2018) 78 (13_Supplement): 744). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ADCT-701 | ADCT701|ADCT 701 | ADCT-701 is an antibody-drug conjugate (ADC) comprising an antibody targeting DLK-1 linked to the cytotoxic agent SG3199, which potentially decreases tumor growth (Cancer Res (2018) 78 (13_Supplement): 744). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06041516 | Phase I | ADCT-701 | Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas | Recruiting | USA | 0 |